Library Subscription: Guest
International Journal of Medicinal Mushrooms

Published 12 issues per year

ISSN Print: 1521-9437

ISSN Online: 1940-4344

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 1.2 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 1.4 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.3 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00066 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.34 SJR: 0.274 SNIP: 0.41 CiteScore™:: 2.8 H-Index: 37

Indexed in

Transcriptome-Wide Analysis Reveals the Molecular Mechanism of Tumoricidal Effects of Lion's Mane Medicinal Mushroom, Hericium erinaceus (Agaricomycetes), on MCF-7 Breast Cancer Cells

Volume 23, Issue 1, 2021, pp. 91-106
DOI: 10.1615/IntJMedMushrooms.2020037448
Get accessGet access

ABSTRACT

Hericium erinaceus (Hericiaceae, Agaricomycetes) is an edible and medicinal mushroom shown to exhibit anticancer effects in various cancers. However, little is known about the effects of H. erinaceus on breast cancer. Here, we aimed to examine the anticancer effects of H. erinaceus water extract on cell viability, apoptosis, and cell cycle distribution in MCF-7 estrogen receptor-positive (ER+) human breast adenocarcinoma cells. We also investigated the possible synergistic interactions between the extract and a known ER antagonist, tamoxifen. Finally, we performed a whole genome transcriptome analysis to investigate the molecular mechanisms underlying the tumoricidal effect of H. erinaceus on breast cancer cells. H. erinaceus water extract was capable of inhibiting cell viability of MCF-7 breast cancer cells in a time- and dose-dependent manner. Treatment with the extract significantly induced apoptosis and G1 cell cycle arrest in cells, consistent with the results of the cell viability analysis. H. erinaceus water extract showed strong synergism with tamoxifen in inhibiting cell viability of MCF-7 cells. The treatment altered the expression of a total of 362 transcripts, including c-Fos, FBJ murine osteosarcoma viral oncogene homolog (FOS), eukaryotic translation initiation factor 1 (EIF1), HES family basic helix-loop-helix transcription factor 1 (HES1), early growth response 2 (EGR2), cyclin L1 (CCNL1), EGR3, Kelch-like family member 24 (KLHL24), and inhibitor of DNA binding 2 (ID2). Results of Gene Ontology enrichment analysis suggest that these genes are mainly associated with transcriptional regulation processes. The cancer signaling pathways that were significantly enriched for differentially expressed genes in response to H. erinaceus treatment were tumor protein P53, Janus kinase−signal transducer and activator of transcription JAK-STAT, transforming growth factor-β, and mitogen-activated protein kinase. Overall, our results provided in vitro evidence that H. erinaceus water extract could be a potent candidate for the treatment of ER+ breast cancer.

REFERENCES
  1. Jiang S, Liu S, Qin M. Effects of extraction conditions on crude polysaccharides and antioxidant activities of the lion's mane medicinal mushroom, Hericium erinaceus (Agaricomycetes). Int J Med Mushrooms. 2019;21(10):1007-18.

  2. Wang M, Konishi T, Gao Y, Xu D, Gao Q. Anti-gastric ulcer activity of polysaccharide fraction isolated from mycelium culture of lion's mane medicinal mushroom, Hericium erinaceus (higher Basidiomycetes). Int J Med Mushrooms. 2015;17(11):1055-60.

  3. Lai PL, Naidu M, Sabaratnam V, Wong KH, David RP, Kuppusamy UR, Abdullah N, Malek SN. Neurotrophic properties of the lion's mane medicinal mushroom, Hericium erinaceus (higher Basidiomycetes) from Malaysia. Int J Med Mushrooms. 2013;15(6):539-54.

  4. He X, Wang X, Fang J, Chang Y, Ning N, Guo H, Huang L, Huang X, Zhao Z. Structures, biological activities, and industrial applications of the polysaccharides from Hericium erinaceus (lion's mane) mushroom: A review. Int J Biol Macromol. 2017;97:228-37.

  5. Mizuno T. Bioactive substances in Hericium erinaceus (Bull.: Fr.) Pers. (Yamabushitake), and its medicinal utilization. Int J Med Mushrooms. 1999;1(2):105-19.

  6. Sangtitanu T, Sangtanoo P, Srimongkol P, Saisavoey T, Reamtong O, Karnchanatat A. Peptides obtained from edible mushrooms: Hericium erinaceus offers the ability to scavenge free radicals and induce apoptosis in lung cancer cells in humans. Food Funct. 2020;11(6):4927-39.

  7. Liu JY, Hou XX, Li ZY, Shan SH, Chang MC, Feng CP, Wei Y. Isolation and structural characterization of a novel polysaccharide from Hericium erinaceus fruiting bodies and its arrest of cell cycle at S-phage in colon cancer cells. Int J Biol Macromol. 2020;157:288-95.

  8. Kim S. Hericium erinaceus isolectins recognize mucin-type O-glycans as tumor-associated carbohydrate antigens on the surface of K562 human leukemia cells. Int J Biol Macromol. 2018;120(Pt A):1093-102.

  9. Zan X, Cui F, Li Y, Yang Y, Wu D, Sun W, Ping L. Hericium erinaceus polysaccharide-protein HEG-5 inhibits SGC-7901 cell growth via cell cycle arrest and apoptosis. Int J Biol Macromol. 2015;76:242-53.

  10. Wang M, Zhang Y, Xiao X, Xu D, Gao Y, Gao Q. A polysaccharide isolated from mycelia of the lion's mane medicinal mushroom Hericium erinaceus (Agaricomycetes) induced apoptosis in precancerous human gastric cells. Int J Med Mushrooms. 2017;19(12):1053-60.

  11. Lee JS, Hong EK. Hericium erinaceus enhances doxorubicin-induced apoptosis in human hepatocellular carcinoma cells. Cancer Lett. 2010;297(2):144-54.

  12. Kim SP, Kang MY, Kim JH, Nam SH, Friedman M. Composition and mechanism of antitumor effects of Hericium erinaceus mushroom extracts in tumor-bearing mice. J Agric Food Chem. 2011;59(18):9861-9.

  13. Kim SP, Nam SH, Friedman M. Hericium erinaceus (lion's mane) mushroom extracts inhibit metastasis of cancer cells to the lung in CT-26 colon cancer-transplanted mice. J Agric Food Chem. 2013;61(20):4898-904.

  14. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27-55.

  15. Pedraza V, Gomez-Capilla JA, Escaramis G, Gomez C, Torne P, Rivera JM, Gil A, Araque P, Olea N, Estivill X, Farez-Vidal ME. Gene expression signatures in breast cancer distinguish phenotype characteristics, histologic subtypes, and tumor invasiveness. Cancer. 2010;116(2):486-96.

  16. Perou CM, S0rlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, L0nning PE, B0rresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumors. Nature. 2000;406(6797):747-52.

  17. Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R; Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793): 771-84.

  18. Palmieri C, Patten DK, Januszewski A, Zucchini G, Howell SJ. Breast cancer: Current and future endocrine therapies. Mol Cell Endocrinol. 2014;382(1):695-723.

  19. Tunjer S, Gurbanov R, Sheraj I, Solel E, Esenturk O, Banerjee S. Low dose dimethyl sulfoxide driven gross molecular changes have the potential to interfere with various cellular processes. Sci Rep. 2018;8(1):14828.

  20. Chen P, Yong Y, Gu Y, Wang Z, Zhang S, Lu L. Comparison of antioxidant and antiproliferation activities of polysaccharides from eight species of medicinal mushrooms. Int J Med Mushrooms. 2015;17(3):287-95.

  21. Kim SP, Kang MY, Choi YH, Kim JH, Nam SH, Friedman M. Mechanism of Hericium erinaceus (Yamabushitake) mushroom-induced apoptosis of U937 human monocytic leukemia cells. Food Funct. 2011;2(6):348-56.

  22. Li G, Yu K, Li F, Xu K, Li J, He S, Cao S, Tan G. Anticancer potential of Hericium erinaceus extracts against human gastrointestinal cancers. J Ethnopharmacol. 2014;153(2):521-30.

  23. Hou XX, Liu JY, Li ZY, Chang MC, Guo M, Feng CP, Shi JY. Fruiting body polysaccharides of Hericium erinaceus induce apoptosis in human colorectal cancer cells via ROS generation mediating caspase-9-dependent signaling pathways. Food Funct. 2020;11(7):6128-38.

  24. Criscitiello C, Fumagalli D, Saini KS, Loi S. Tamoxifen in early-stage estrogen receptor-positive breast cancer: Overview of clinical use and molecular biomarkers for patient selection. Onco Targets Ther. 2010;4:1-11.

  25. Chiu R, Boyle WJ, Meek J, Smeal T, Hunter T, Karin M. The c-Fos protein interacts with c-Jun/AP-1 to stimulate transcription of AP-1 responsive genes. Cell. 1988;54(4):541-52.

  26. Shaulian E, Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol. 2002;4(5):E131-6.

  27. Eferl R, Wagner EF. AP-1: A double-edged sword in tumorigenesis. Nat Rev Cancer. 2003;3(11):859-68.

  28. Pestova TV, Kolupaeva VG. The roles of individual eukaryotic translation initiation factors in ribosomal scanning and initiation codon selection. Genes Dev. 2002;16(22):2906-22.

  29. Golob-Schwarzl N, Schweiger C, Koller C, Krassnig S, Gogg-Kamerer M, Gantenbein N, Toeglhofer AM, Wodlej C, Bergler H, Pertschy B, Uranitsch S, Holter M, El-Heliebi A, Fuchs J, Punschart A, Stiegler P, Keil M, Hoffmann J, Henderson D, Lehrach H, Reinhard C, Regenbrecht C, Schicho R, Fickert P, Lax S, Haybaeck J. Separation of low and high grade colon and rectum carcinoma by eukaryotic translation initiation factors 1, 5 and 6. Oncotarget. 2017;8(60):101224-43.

  30. van Agthoven T, Sieuwerts AM, Meijer D, Meijer-van Gelder ME, van Agthoven TL, Sarwari R, Sleijfer S, Foekens JA, Dorssers LC. Selective recruitment of breast cancer anti-estrogen resistance genes and relevance for breast cancer progression and tamoxifen therapy response. Endocr Relat Cancer. 2010;17(1):215-30.

  31. Wang X, Fu Y, Chen X, Ye J, Lu B, Ye F, Lu W, Xie X. The expressions of bHLH gene HES1 and HES5 in advanced ovarian serous adenocarcinomas and their prognostic significance: A retrospective clinical study. J Cancer Res Clin Oncol. 2010;136(7):989-96.

  32. Konishi J, Kawaguchi KS, Vo H, Haruki N, Gonzalez A, Carbone DP, Dang TP. Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers. Cancer Res. 2007;67(17):8051-7.

  33. Li X, Cao Y, Li M, Jin F. Upregulation of HES1 promotes cell proliferation and invasion in breast cancer as a prognosis marker and therapy target via the AKT pathway and EMT process. J Cancer. 2018;9(4):757-66.

  34. Iyer VR, Eisen MB, Ross DT, Schuler G, Moore T, Lee JC, Trent JM, Staudt LM, Hudson J Jr, Boguski MS, Lashkari D, Shalon D, Botstein D, Brown PO. The transcriptional program in the response of human fibroblasts to serum. Science. 1999;283(5398):83-7.

  35. Berke JD, Sgambato V, Zhu PP, Lavoie B, Vincent M, Krause M, Hyman SE. Dopamine and glutamate induce distinct striatal splice forms of Ania-6, an RNA polymerase II-associated cyclin. Neuron. 2001;32(2):277-87.

  36. Sticht C, Hofele C, Flechtenmacher C, Bosch FX, Freier K, Lichter P, Joos S. Amplification of Cyclin L1 is associated with lymph node metastases in head and neck squamous cell carcinoma (HNSCC). Br J Cancer. 2005;92(4):770-4.

  37. Suzuki T, Inoue A, Miki Y, Moriya T, Akahira J, Ishida T, Hirakawa H, Yamaguchi Y, Hayashi S, Sasano H. Early growth responsive gene 3 in human breast carcinoma: A regulator of estrogen-meditated invasion and a potent prognostic factor. Endocr Relat Cancer. 2007;14(2):279-92.

  38. Fei Y, Yu H, Huang S, Chen P, Pan L. Expression and prognostic analyses of early growth response proteins (EGRs) in human breast carcinoma based on database analysis. PeerJ. 2019;7:e8183.

  39. Bockers M, Paul NW, Efferth T. Organophosphate ester tri-o-cresyl phosphate interacts with estrogen receptor a in MCF-7 breast cancer cells promoting cancer growth. Toxicol Appl Pharmacol. 2020;395:114977.

  40. Sun XH, Copeland NG, Jenkins NA, Baltimore D. Id proteins Id1 and Id2 selectively inhibit DNA binding by one class of helix-loop-helix proteins. Mol Cell Biol. 1991;11(11):5603-11.

  41. Florio M, Hernandez MC, Yang H, Shu HK, Cleveland JL, Israel MA. Id2 promotes apoptosis by a novel mechanism independent of dimerization to basic helix-loop-helix factors. Mol Cell Biol. 1998;18(9):5435.

  42. Stighall M, Manetopoulos C, Axelson H, Landberg G. High ID2 protein expression correlates with a favorable prognosis in patients with primary breast cancer and reduces cellular invasiveness of breast cancer cells. Int J Cancer. 2005;115(3):403-11.

  43. Itahana Y, Singh J, Sumida T, Coppe JP, Parrinello S, Bennington JL, Desprez PY. Role of Id-2 in the maintenance of a differentiated and noninvasive phenotype in breast cancer cells. Cancer Res. 2003;63(21):7098-105.

  44. Li K, Yao L, Chen L, Cao ZG, Yu SJ, Kuang XY, Hu X, Shao ZM. ID2 predicts poor prognosis in breast cancer, especially in triple-negative breast cancer, and inhibits E-cadherin expression. Onco Targets Ther. 2014;7:1083-94.

  45. Issaeva N. p53 signaling in cancers. Cancers. 2019;11(3):332.

  46. Luo N, Balko JM. Role of JAK-STAT pathway in cancer signaling. In: Badve S, Kumar GL, editors. Predictive biomarkers in oncology. Cham, Switzerland: Springer; 2019. p. 311-9.

  47. Syed V. TGF-P signaling in cancer. J Cell Biochem. 2016;117(6):1279-87.

  48. Braicu C, Buse M, Busuioc C, Drula R, Gulei D, Raduly L, Rusu A, Irimie A, Atanasov AG, Slaby O, Ionescu C, Berindan-Neagoe I. A comprehensive review on MAPK: A promising therapeutic target in cancer. Cancers. 2019;11(10):1618.

CITED BY
  1. Liu Jianhui, Wang Weiwei, Hu Qiuhui, Wu Xuyang, Xu Hui, Su Anxiang, Xie Minhao, Yang Wenjian, Bioactivities and molecular mechanisms of polysaccharides from Hericium erinaceus, Journal of Future Foods, 2, 2, 2022. Crossref

Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections Prices and Subscription Policies Begell House Contact Us Language English 中文 Русский Português German French Spain